AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 112 min read$INNV

InnovAge (INNV) Reaches a 9.6% Adjusted EBITDA Margin. Can the PACE Recovery Last?

InnovAge (INNV) reported fiscal 2026 revenue of $989.7M, up 15.9%, with adjusted EBITDA of $94.6M. Adjusted EBITDA margin rose to 9.6% from 4.0%. GAAP net loss narrowed to $0.7M. Fiscal 2027 guidance projects revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. The company did not forecast GAAP net income due to estimation challenges.

Original reporting
yahoo.com
Published Sep 11, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
InnovAge (INNV) Reaches a 9.6% Adjusted EBITDA Margin. Can the PACE Recovery Last? — source image
Source · yahoo.com
Decision brief

The 30-second read

$INNVBullishHigh
01

Why it matters

The earnings beat and guidance may trigger short covering and new buying, but litigation cost adjustments warrant close monitoring.

02

Market read

First‑report earnings and guidance for a mid‑cap healthcare provider, offering actionable insight for traders.

03

What to watch

Potential staffing and medical cost pressures could erode future margins despite current growth.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

InnovAge operates PACE programs for seniors, reporting a significant recovery in earnings and providing optimistic FY2027 guidance.

Company-level read

Ticker impact

$INNVBullishHigh confidence
Context

InnovAge Holding Corp. reported FY2026 revenue of $989.7M and adjusted EBITDA margin of 9.6%, plus FY2027 guidance of $1.05‑$1.085B revenue and $105‑$115M EBITDA.

Expected impact

Potential upside of 5‑10% if market digests the earnings beat and guidance.

Evidence & confidence

Revenue growth and margin expansion exceed prior year, while GAAP loss narrows; however, litigation cost add‑backs introduce uncertainty.

Market effects

Sector

Positive signal for the senior‑care PACE sector, suggesting improved economics may benefit peers.

Regional

U.S. healthcare services segment may see modest buying pressure.

Global

Limited to U.S. healthcare investors; no broader macro effect.

Counterpoint

What could challenge this read

Litigation cost add‑backs could mask underlying cash flow weakness; caution on upside.

Key entities

  • company
    InnovAge Holding Corp.

    NASDAQ‑listed senior‑care provider.

Read at source← All news

Related articles

SEP 10
$INNVMedAI 8/10

InnovAge Holding Corp. Q4 2026 Earnings Call Summary

InnovAge Holding Corp. completed 'InnovAge 2.0' in 2026, focusing on operational improvements. 'InnovAge 3.0' will prioritize scaling and expansion. For 2027, the company projects 1.5% to 2.0% net Medicare rate increases and revenue of $1.05B to $1.085B, with growth driven by enrollment and utilization management. Management prefers M&A over de novo centers for capital allocation.

yahoo.com3 min
SEP 9
$INNVHighAI 8/10

InnovAge (INNV) Q4 2026 Earnings Call Transcript

InnovAge (INNV) reported Q4 2026 revenue of $262.0M, up 18.3% YoY, and net income of $9.8M. Full-year revenue rose 15.9% to $989.7M, with adjusted EBITDA increasing 174.2% to $94.6M. The company guided FY 2027 revenue to $1.05B-$1.085B and adjusted EBITDA to $105M-$115M, citing census growth and rate increases. Management highlighted expansion plans and potential M&A activity, while noting risks from Medicaid rate uncertainties in key states.

fool.com3 min
SEP 9
$INNVHighAI 9/10

InnovAge shares jump 13% as fiscal 2027 guidance tops $1bn

InnovAge Holding Corp (INNV) reported fiscal 2026 results and fiscal 2027 guidance of $1.05bn to $1.085bn in revenue. Shares rose 13.12% to $11.90. Management reported a 175% increase in adjusted EBITDA, though GAAP net income showed volatility. The company plans to scale operations and expand value-based care. Three private-equity sponsors filed SEC forms around the earnings release.

financial-news.co.uk2 min
SEP 9
$INNVHighAI 8/10

Why is InnovAge stock up 14% today?

InnovAge (INNV) stock rose 14.6% in pre-market trading after reporting fiscal Q4 and full-year 2026 results. Adjusted EBITDA increased 175% to $94.6M, revenue grew 15.9% to $989.7M, and net loss narrowed to $0.7M. The company issued fiscal 2027 guidance targeting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. CEO Patrick Blair highlighted a strategic focus on scaling through technology, AI, and potential acquisitions.

investing.com2 min
SEP 8
$INNVMedAI 9/10

InnovAge Q4 Earnings Call Highlights

InnovAge reported Q4 cost of care rose 16.1% to $312.1M. It held $97.9M in cash, $43.4M in short-term investments, and $63.3M in debt. The company projected fiscal 2027 revenue of $1.05B-$1.085B, adjusted EBITDA of $105M-$115M, and 5%-7.5% growth. It outlined 'InnovAge 3.0' strategy, focusing on scaling and acquisitions.

yahoo.com2 min